Provention Bio names new SVP of Clinical Development
18 November 2021 -

Provention Bio, Inc. (Nasdaq: PRVB), a US-based biopharmaceutical company, announced on Wednesday that it has named Jan Hillson, MD as its new senior vice president of Clinical Development.

Dr Hillson has more than two decades of experience in academic research, patient care, teaching and directing strategy and operations of clinical research and translational medicine programs. He has served as senior vice president, Clinical Development at Alpine Immune Sciences, senior vice president of Clinical and Translational Research at ChemoCentryx, and in roles of increasing responsibility at Momenta Pharmaceuticals, ZymoGenetics, Bristol Myers Squibb and Xcyte Therapies. He was a member of the clinical faculty of Harvard Medical School, assistant professor at the University of Washington, and division head of Rheumatology at Virginia Mason Medical Center. Presently, he serves on the board of directors at Eledon Pharmaceuticals.

Dr Hillson holds MD from Stanford School of Medicine, an MS in Environmental Engineering from the California Institute of Technology, an MS in Marine Chemistry from Scripps Institute of Oceanography, and a BS from Michigan State University.